RxDoctor Payments Data

Sean Saedi, MD

Internal Medicine · Silver Spring, MDNPI 1003896234

Payments from drug & device makers

$12,490in general payments, 2019–2025

Across 711 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Amgen$1K
  • AstraZeneca$1K
  • Pfizer$760
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$12,19998%
  • Education$2912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,490 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$169,692
Medicare patients
683
Services billed
2,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide241$449,957
JardianceEmpagliflozin261$399,218
MounjaroTirzepatide160$311,302
EliquisApixaban173$244,707
FarxigaDapagliflozin Propanediol100$151,687
TrulicityDulaglutide44$84,287
MyrbetriqMirabegron47$53,397
CreonLipase/Protease/Amylase11$50,485
JanuviaSitagliptin Phosphate33$44,168
XareltoRivaroxaban32$40,946
EntrestoSacubitril/Valsartan26$39,699
LinzessLinaclotide19$31,349
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$24,163
Cinacalcet Hcl14$19,901
Tresiba Flextouch U-200Insulin Degludec14$18,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,213$449,957241 claims
Boehringer IngelheimJardiance$533$399,218261 claims
Lilly USA, LLCMounjaro, Trulicity$1,344$395,589204 claims
PfizerEliquis, Paxlovid$760$248,995213 claims
AstraZenecaFarxiga, Symbicort$1,025$159,363121 claims
AbbVieCreon, Linzess, Synthroid$1,143$85,334106 claims
Astellas Pharma US IncMyrbetriq$578$53,39747 claims
MerckJanuvia, Dulera$290$50,66448 claims
Johnson & JohnsonXarelto$397$40,94632 claims
NovartisEntresto$366$39,69926 claims
GSKTrelegy Ellipta$605$24,16316 claims
GileadVemlidy$74$16,48312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →